Summary
Boston Scientific Corporation (BSX) announced a significant event impacting its structural heart business. The company has initiated a voluntary global recall of all unused inventory for its LOTUS Edge Aortic Valve System and will immediately retire the entire LOTUS platform. This decision stems from the company's strategic review and is effective immediately. This product discontinuation is estimated to result in pre-tax charges ranging from $225 million to $300 million. A substantial portion of these charges, primarily inventory write-offs and restructuring expenses, are expected to be recognized in the fourth quarter of 2020. While the recall impacts a specific product line, investors should monitor the company's subsequent filings for a clearer picture of the financial impact and any strategic shifts in its cardiovascular division.
Key Highlights
- 1Boston Scientific is voluntarily recalling all unused inventory of its LOTUS Edge Aortic Valve System.
- 2The company has made the decision to immediately retire the entire LOTUS platform.
- 3An estimated pre-tax charge of $225 million to $300 million is expected due to this discontinuation.
- 4The majority of these charges are anticipated to be recorded in the fourth quarter of 2020.
- 5Inventory write-offs are estimated to be between $100 million and $150 million.
- 6Restructuring charges and related expenses are projected to be between $115 million and $140 million ($45-60M exit costs + $70-80M restructuring-related expenses).
- 7Only $50 million to $100 million of the total estimated charges are expected to result in future cash outlays.